Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Novartis' Rhapsido (remibrutinib) wins FDA label expansion for symptomatic dermographism based on Ph3 data
Small molecule, autoimmune, BTK inhibitor, chronic urticaria, multiple sclerosis - Read more

FDA approves Pfizer's Tukysa (tucatinib) for first-line HER2-positive breast cancer maintenance based on Ph3 data
Small molecule, cancer, tyrosine kinase inhibitor, breast cancer, HER2 - Read more

Theramex licenses Asieris' HPV cervical lesion treatment Cevira for Europe, $15M upfront, $250M total
Licensing deal, women's health, drug-device combination, milestone payments, royalties - Read more

Cadrenal Therapeutics launches strategic review exploring licensing, partnerships, or sale of cardiology pipeline
Strategic review, cardiology, small molecule, licensing deal, rare disease - Read more

Ono Pharmaceutical licenses three Biohaven IgG degraders for Asia-Pacific rights, $80M upfront, $20M milestone
Licensing deal, autoimmune, protein degraders, milestone payments, royalties - Read more

Ultragenyx Pharmaceutical sells Genglycos-derived priority review voucher for $210M cash
Priority review voucher, rare disease, gene therapy, licensing deal, royalties - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

argenx's FB102 (anti-CD122 antibody) hits primary endpoint in Ph2 trial for coeliac disease
Antibody, autoimmune, monoclonal antibody, coeliac disease, CD122 target - Read more

Endeavor BioMedicines' (taladegib) meets Ph2b primary endpoint, potentially reversing idiopathic pulmonary fibrosis via Hedgehog inhibition
Small molecule, pulmonary fibrosis, Hedgehog inhibitor, idiopathic pulmonary fibrosis, fibroblast targeting - Read more

Atrogi reports positive Ph1 human data for (ATR-258), GRK2-biased β2-adrenergic modulator, showing muscle and fat composition gains
Small molecule, metabolic, β2-adrenergic modulator, GRK2 inhibitor, sarcopenia, muscle wasting - Read more

Bristol Myers Squibb's Zenbexus (iberdomide) hits Ph3 progression-free survival endpoint in relapsed or refractory multiple myeloma
Small molecule, cancer, CELMoD, multiple myeloma, combination therapy, cereblon E3 ligase - Read more

Iambic Therapeutics aims for $135M IPO to advance AI-driven cancer drug pipeline
AI/ML platform, oncology, small molecule, clinical-stage, platform-enabled - Read more

Biohub's Virtual Biology Initiative reaches $1.8B in combined funding, AI-ready biological data
AI/ML platform, virtual biology, platform technology, protein design, biomarker discovery - Read more

PhRMA sues to block CMS's GLOBE Medicare Part B drug pricing model, citing unlawful overreach
Medicare Part B, drug pricing, regulatory, financial - Read more

Viatris to acquire Pacira BioSciences for $1.65B, expanding non-opioid pain management portfolio
Small molecule, pain management, major transaction, strategic - Read more

Laverock Therapeutics unveils new in vivo CAR-T and genetic medicine programmes, expanding oncology pipeline
In vivo cell therapy, oncology, gene therapy, rare disease, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Newron Pharmaceuticals reveals 5 deaths in schizophrenia trial as FDA maintains clinical hold on evenamide
Small molecule, neurological, safety, regulatory - Read more

Zealand Pharma, Roche's (petrelintide) Ph2 data show weight loss promise but weak blood sugar results in type 2 diabetes
Protein therapy, metabolic, amylin analog, obesity, type 2 diabetes, GLP-1 - Read more

Argenx halts Ph3 trial of Vyvgart Hytrulo (efgartigimod alfa) in Sjogren's disease due to futility
Antibody, autoimmune, monoclonal antibody, Sjogren's disease, FcRn inhibitor - Read more

CSL Seqirus sanctioned by UK watchdog for undisclosed £700K+ ($925K+) payments, systemic governance failures
Flu vaccine, infectious disease, compliance, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here